---
title: "Vax appoints James B. Breitmeyer to its Board"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283892156.md"
description: "Vax has appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors, effective immediately. He is the current CEO of Altay Therapeutics and has extensive experience in the biotech sector. The Board has determined that he meets independence standards and will receive standard compensation and indemnification. This appointment follows a recommendation by the Nominating and Governance Committee."
datetime: "2026-04-23T20:53:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283892156.md)
  - [en](https://longbridge.com/en/news/283892156.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283892156.md)
generator: "portal-rs"
---

# Vax appoints James B. Breitmeyer to its Board

**Vax appointed James B. Breitmeyer, M.D., Ph.D. to its Board, effective immediately.**

**Individual**

James B. Breitmeyer, M.D., Ph.D.

**Role**

Director

**Type of Change**

Appointed

**Effective Date**

April 23, 2026

**Reason**

Board appointment following recommendation by the Nominating and Governance Committee

**Replacement Info**

Not disclosed

**Background Details**

Current CEO and director of Altay Therapeutics; former CEO of Oncternal Therapeutics (2016–2025); extensive biotech executive experience in development and operations; M.D. and Ph.D.; board-certified in Internal Medicine and Oncology.

**Board/Committee Role Changes**

Board determined he meets independence standards; entitled to standard cash and equity director compensation and the company's indemnification agreement.

Original SEC Filing: Vaxart, Inc. \[ VXRT \] - 8-K - Apr. 23, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CYTOF.US](https://longbridge.com/en/quote/CYTOF.US.md)
- [VXRT.US](https://longbridge.com/en/quote/VXRT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [NBSE.ESC.US](https://longbridge.com/en/quote/NBSE.ESC.US.md)
- [ALTG.US](https://longbridge.com/en/quote/ALTG.US.md)
- [NA.US](https://longbridge.com/en/quote/NA.US.md)
- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)
- [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md)
- [BVNRY.US](https://longbridge.com/en/quote/BVNRY.US.md)
- [MR7.SG](https://longbridge.com/en/quote/MR7.SG.md)
- [NORD.US](https://longbridge.com/en/quote/NORD.US.md)
- [BAVA.US](https://longbridge.com/en/quote/BAVA.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [CDNS.US](https://longbridge.com/en/quote/CDNS.US.md)
- [CDM.AU](https://longbridge.com/en/quote/CDM.AU.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [AXGN.US](https://longbridge.com/en/quote/AXGN.US.md)
- [4250.JP](https://longbridge.com/en/quote/4250.JP.md)
- [3962.JP](https://longbridge.com/en/quote/3962.JP.md)
- [OKUR.US](https://longbridge.com/en/quote/OKUR.US.md)
- [TNON.US](https://longbridge.com/en/quote/TNON.US.md)
- [ALTG-A.US](https://longbridge.com/en/quote/ALTG-A.US.md)
- [TNONW.US](https://longbridge.com/en/quote/TNONW.US.md)

## Related News & Research

- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)
- [Vaxart urges shareholders to back its six director nominees at July 16 annual meeting amid dissident challenge](https://longbridge.com/en/news/290961750.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**